Denis Villemagne

发表

Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates

B. Bosch, A. Lehmann, H. Binz, 2020, bioRxiv.

Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins

U. Fiedler, Jennifer Krieg, D. Snell, 2020, Journal of immunology research.

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants

A. Gruber, B. Bosch, H. Binz, 2022, Nature biotechnology.

Highly efficient ribosome display selection by use of purified components for in vitro translation.

J. Douthwaite, Denis Villemagne, R. Jackson, 2006, Journal of immunological methods.

Targeting Extracellular Domains D4 and D7 of Vascular Endothelial Growth Factor Receptor 2 Reveals Allosteric Receptor Regulatory Sites

H. Binz, K. Ballmer-Hofer, E. Stuttfeld, 2012, Molecular and Cellular Biology.

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications

H. Binz, P. Forrer, M. Stumpp, 2012, Angiogenesis.

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications

H. Binz, P. Forrer, M. Stumpp, 2012, Angiogenesis.

Half-life extension using serum albumin-binding DARPin® domains

H. Binz, P. Forrer, M. Stumpp, 2017, Protein engineering, design & selection : PEDS.

MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells

D. Steiner, V. Kirkin, M. Hänggi, 2022, Blood.